Logo Logo Logo Logo Logo
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Partnering
  • Careers
  • Contact us
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Partnering
  • Careers
  • Contact us

10 Mar Recent news

Posted at 17:05h in by Complix

Recent news

Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
Print page


About Complix
Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics active against cutting-edge and challenging intracellular targets that play a key role in life threatening diseases, including cancer.
Recent news
  • Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances March 31, 2021
  • Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets March 10, 2021
  • Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody™ therapeutics October 7, 2020
Complix newsletter
Subscribe to the Complix newsletter & stay up to date with news, events & projects.
Contact us
Technologiepark 94
9052 Zwijnaarde (Ghent)
Belgium
Phone: +32 (0)9 261 69 40
Fax: +32 (0)9 261 69 50
E-Mail: info@complix.com
© 2020 Complix | Terms of use | Privacy policy | Cookie policy